Roche Holding AG (ROGZ.XC)
Cboe UK - Cboe UK Real-time price. Currency in CHF
Add to watchlist
At close: 04:19PM BST
| Previous close | 250.80 |
| Open | 251.10 |
| Bid | 249.50 x 0 |
| Ask | 249.70 x 0 |
| Day's range | 249.40 - 252.30 |
| 52-week range | 213.00 - 277.90 |
| Volume | |
| Avg. volume | 179,939 |
| Market cap | 201.505B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 17.45 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.60 (3.85%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Zacks
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
- Zacks
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
- Zacks
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
© 2024 Yahoo. All rights reserved.